Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
663 participants
OBSERVATIONAL
2017-12-21
2024-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Profile and incidence of ADRs The CEI will be conducted to collect data of the events, especially focusing on bleeding, dyspnoea and bradyarrhythmia so as to investigate onset, outcome, treatment for the event, and risk factors for these events, etc.
2. Profile and incidence of ADRs not expected from "Precautions for Use" of the ticagrelor JPI
3. Efficacy: Profile and incidence of cardiovascular events (cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke)
4. Factors which may affect safety or efficacy of ticagrelor
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta
NCT01611272
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study
NCT04609111
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
NCT00508924
A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention
NCT00291902
Prospective Real-world Registry Describing Treatment Regimens
NCT03942913
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Aichi, , Japan
Research Site
Aichi, , Japan
Research Site
Aichi, , Japan
Research Site
Akita, , Japan
Research Site
Chiba, , Japan
Research Site
Chiba, , Japan
Research Site
Fukuoka, , Japan
Research Site
Fukuoka, , Japan
Research Site
Fukuoka, , Japan
Research Site
Fukuoka, , Japan
Research Site
Gunma, , Japan
Research Site
Gunma, , Japan
Research Site
Hokkaido, , Japan
Research Site
Hokkaido, , Japan
Research Site
Hokkaido, , Japan
Research Site
Hokkaido, , Japan
Research Site
Hokkaido, , Japan
Research Site
Hokkaido, , Japan
Research Site
Hyōgo, , Japan
Research Site
Hyōgo, , Japan
Research Site
Hyōgo, , Japan
Research Site
Hyōgo, , Japan
Research Site
Hyōgo, , Japan
Research Site
Ibaraki, , Japan
Research Site
Ibaraki, , Japan
Research Site
Ibaraki, , Japan
Research Site
Kagoshima, , Japan
Research Site
Kanagawa, , Japan
Research Site
Kanagawa, , Japan
Research Site
Kanagawa, , Japan
Research Site
Kanagawa, , Japan
Research Site
Kochi, , Japan
Research Site
Kumamoto, , Japan
Research Site
Mie, , Japan
Research Site
Mie, , Japan
Research Site
Miyagi, , Japan
Research Site
Nagasaki, , Japan
Research Site
Okayama, , Japan
Research Site
Okayama, , Japan
Research Site
Okinawa, , Japan
Research Site
Okinawa, , Japan
Research Site
Okinawa, , Japan
Research Site
Osaka, , Japan
Research Site
Osaka, , Japan
Research Site
Osaka, , Japan
Research Site
Osaka, , Japan
Research Site
Osaka, , Japan
Research Site
Osaka, , Japan
Research Site
Osaka, , Japan
Research Site
Osaka, , Japan
Research Site
Osaka, , Japan
Research Site
Ōita, , Japan
Research Site
Saitama, , Japan
Research Site
Saitama, , Japan
Research Site
Saitama, , Japan
Research Site
Shiga, , Japan
Research Site
Shiga, , Japan
Research Site
Shizuoka, , Japan
Research Site
Tochigi, , Japan
Research Site
Tochigi, , Japan
Research Site
Tokyo, , Japan
Research Site
Tokyo, , Japan
Research Site
Tokyo, , Japan
Research Site
Tokyo, , Japan
Research Site
Tokyo, , Japan
Research Site
Tokyo, , Japan
Research Site
Wakayama, , Japan
Research Site
Wakayama, , Japan
Research Site
Wakayama, , Japan
Research Site
Yamagata, , Japan
Research Site
Yamanashi, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D5133N00007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.